<DOC>
	<DOCNO>NCT00983372</DOCNO>
	<brief_summary>Colchicine substrate cytochrome P450 3A4 ( CYP3A4 ) P-glycoprotein ( P-gp ) . Extended-release diltiazem ( diltiazem ER ) potent inhibitor CYP3A4 P-gp . This study evaluate effect multiple dos diltiazem ER pharmacokinetic profile single 0.6 mg dose colchicine . A secondary objective evaluate safety tolerability regimen healthy volunteer . All study subject monitor adverse event throughout study period .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Between Colchicine Diltiazem ER</brief_title>
	<detailed_description>Colchicine substrate cytochrome P450 3A4 ( CYP3A4 ) P-glycoprotein ( P-gp ) . Extended-release diltiazem ( diltiazem ER ) potent inhibitor CYP3A4 P-gp . This study evaluate effect multiple dos diltiazem ER pharmacokinetic profile single 0.6mg dose colchicine . On Day 1 fast least 10 hour , twenty-four healthy , non-smoking , non-obese , non-pregnant adult volunteer age 18 45 give single oral dose colchicine ( 1 x 0.6 mg tablet ) . Fasting continue 4 hour dose . Blood sample draw participant dose twenty-four hour post-dose confined basis time sufficient adequately define pharmacokinetics colchicine . Blood sample continue non-confined basis 36 , 48 , 72 , 96 hour post-dose . After 14-day washout period , begin Day 15 continue Day 20 subject return clinic non-confined dosing diltiazem ER ( 1 x 240 mg capsule daily ) . Administered diltiazem ER dose day necessarily fast state . On Day 21 fast least 10 hour , study participant receive co-administered single oral dose colchicine ( 1 x 0.6 mg tablet ) diltiazem ER ( 1 x 240 mg capsule ) . Blood sample draw participant dose twenty-four hour post-dose confined basis time sufficient adequately define pharmacokinetics colchicine presence diltiazem ER steady state . Blood sample continue non-confined basis 36 , 48 , 72 , 96 hour post-dose administration . Fasting continue 4 hour follow co-administered dose colchicine diltiazem ER . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Vital sign ( blood pressure pulse ) measure pre-dose 1 , 2 , 3 hour post-dosing Day 1 , pre-dose 12 hour post-dosing Day 15 ( subject return study center 12-hour post-dose vital sign measurement ) , pre-dose 1 , 2 , 3 12 hour post-dosing Day 21 coincide peak plasma concentration colchicine diltiazem . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Healthy adult 1845 year age , nonsmoking nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) body mass index ( BMI ) great equal 18 less equal 32 , inclusive . Recent participation ( within 28 day ) research study Recent significant blood donation plasma donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study Drug allergy colchicine diltiazem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>healthy ; adult ; volunteer ; colchicine ; diltiazem ; blood level time</keyword>
</DOC>